Table 5

The proportion of comorbidities in patients with COVID-19 at baseline by continent

RefMalignancyEndocrine systemRenal systemNeurological systemCardiovascular systemRespiratory system
DiabetesKidney diseaseCKDCerebrovascular diseaseCardiovascular diseaseHypertensionRespiratory diseasePulmonary diseaseCOPD
America (North)10NDNDNDNDNDNDNDNDNDND
15
11334833
Range334833
Asia9ND7NDNDND1166NDND
26711315ND1
38316226303
55NDNDNDNDNDNDND
4301022*22†2
44ND5ND314ND
4511918303
47NDNDNDDNQDNQ0ND
275104510243
22NDNDNDNDNDNDND
361215301
197103ND515313
34210NDND7102
493951010
56NDNDNDNDNDND
57
1716*16†5
39140*40†1
41ND93*3†17ND
588ND166
59263191
2551247101511
371ND1ND3131ND10
48ND25NDNDND40ND10
60NDNDND
50101213106
4272ND7NDND
2922282
78NDND2208
40731118ND
18NDNDND15
304171410ND8
20ND86ND105
286ND210ND2
61DNQDNQDNQND
6222015152
24912182463
46613313622ND6
13ND22ND4111941ND
12DNQNDNDDNQND
8NDND
63
3511
21ND
66
16ND
2317173325
64NDNDNDND
65DNQDNQDNQ
32NDNDND
31
33
Range(0–9)(2–25)(1–6)(1–17)(1–40)(1–40)(0–40)(1–41)(1–10)(0–11)
Europe14NDNDNDNDNDNDNDNDNDND
Range
Range(0–9)(2–33)(1–6)(0–48)(1–40)(1–40)(0–40)(1–41)(1–10)(0–33)
  • *Or cardiovascular disease.

  • †Or cerebrovascular disease.

  • CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DNQ, described but not quantified; ND, not described; Ref, reference.